Galecto
GLTOGalecto, Inc. (NASDAQ: GLTO) is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark. The company's primary business focus is the research and development of novel small-molecule therapeutics designed to inhibit galectin proteins. Galectins are implicated in the underlying biology of fibrosis, inflammation, and cancer, making them targets for therapeutic intervention. The company's pipeline is concentrated on treating fibrosis and related diseases. Its lead product candidate, GB1211, is an oral galectin-3 inhibitor that has been evaluated in clinical trials for non-alcoholic steatohepatitis (NASH) with liver fibrosis and in combination with atezolizumab for certain lung cancers. Galecto's development strategy is centered on advancing GB1211 and other inhibitors through clinical testing to address serious conditions with high unmet medical need. As a publicly traded entity, Galecto operates within the biotechnology and fibrosis therapeutics sectors. The company's work is based on a platform targeting galectin biology, with the goal of generating clinical data to demonstrate the safety and efficacy of its candidates. Its research activities and trial results are documented in public regulatory filings and scientific communications.
GLTO · Stock Price
Historical price data
About
Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark. The company's primary business focus is the research and development of novel small-molecule therapeutics designed to inhibit galectin proteins. Galectins are implicated in the underlying biology of fibrosis, inflammation, and cancer, making them targets for therapeutic intervention. The company's pipeline is concentrated on treating fibrosis and related diseases. Its lead product candidate, GB1211, is an oral galectin-3 inhibitor that has been evaluated in clinical trials for non-alcoholic steatohepatitis (NASH) with liver fibrosis and in combination with atezolizumab for certain lung cancers. Galecto's development strategy is centered on advancing GB1211 and other inhibitors through clinical testing to address serious conditions with high unmet medical need. As a publicly traded entity, Galecto operates within the biotechnology and fibrosis therapeutics sectors. The company's work is based on a platform targeting galectin biology, with the goal of generating clinical data to demonstrate the safety and efficacy of its candidates. Its research activities and trial results are documented in public regulatory filings and scientific communications.